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Objective. Classiﬁcation criteria for systemic sclerosis (SSc; scleroderma) are being updated. Our objective was to select
a set of items potentially useful for the classiﬁcation of SSc using consensus procedures, including the Delphi and nominal
group techniques (NGT).
Methods. Items were identiﬁed through 2 independent consensus exercises performed by the Scleroderma Clinical Trials
Consortium and the European League Against Rheumatism Scleroderma Trials and Research Group. The ﬁrst-round
items from both exercises were collated and redundancies were removed, leaving 168 items. A 3-round Delphi exercise
was performed using a 1–9 scale (where 1  completely inappropriate and 9  completely appropriate) and a consensus
meeting using NGT was conducted. During the last Delphi round, the items were ranked on a 1–10 scale.
Results. In round 1, 106 experts rated the 168 items. Those with a median score of <4 were removed, resulting in a list
of 102 items. In round 2, the items were again rated for appropriateness and subjected to a consensus meeting using NGT
by European and North American SSc experts (n  16), resulting in 23 items. In round 3, SSc experts (n  26) then
individually scored each of the 23 items in a last Delphi round using an appropriateness score (1–9) and ranking their 10
most appropriate items for the classiﬁcation of SSc. Presence of skin thickening, SSc-speciﬁc autoantibodies, abnormal
nailfold capillary pattern, and Raynaud’s phenomenon ranked highest in the ﬁnal list that also included items indicating
internal organ involvement.
Conclusion. The Delphi exercise and NGT resulted in a set of 23 items for the classiﬁcation of SSc that will be assessed
for their discriminative properties in a prospective study.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a complex multi-
system autoimmune disease of which the pathogenesis is
not completely understood (1). The 3 hallmark manifesta-
tions of the pathogenic process are vasculopathy of small
vessels resulting in tissue ischemia, an immune response
manifested as altered T and B lymphocyte function and
production of autoantibodies, and ﬁbroblast dysfunction
leading to increased deposition of the extracellular matrix
(2).
The current classiﬁcation criteria for SSc were devel-
oped in1980 by a subcommittee of the American College of
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Rheumatology (ACR) (3). The ACR criteria were not in-
tended for diagnostic purposes but for inclusion of pa-
tients in clinical studies (Table 1). ACR criteria were de-
veloped using patients with longstanding diffuse
cutaneous SSc. As a consequence, patients with early SSc
and a signiﬁcant proportion of patients with limited cuta-
neous SSc (lcSSc) do not meet the current criteria (4–6).
Since the development of the 1980 criteria (3), knowl-
edge regarding the association of SSc-speciﬁc autoantibod-
ies with different SSc phenotypes has improved (4,5). In
addition, characteristic nailfold capillary changes have
been found to be associated with the development of SSc
(6,7), and nailfold capillaroscopy is widely accepted as a
diagnostic tool (7–9). In 2001, LeRoy and Medsger pro-
posed to revise the classiﬁcation criteria to include “early”
cases of SSc (10). They suggested that patients may be
classiﬁed as limited SSc (or “pre-SSc” or “unclassiﬁable
SSc”) when having Raynaud’s phenomenon (RP), a SSc-
speciﬁc nailfold capillary pattern, and/or SSc-speciﬁc au-
toantibodies (10). The validity of the proposed criteria was
supported in 2008 by a large cohort of patients with RP (7).
The presence of SSc-speciﬁc autoantibodies and microvas-
cular damage (as assessed by nailfold capillaroscopy) was
predictive for the development of SSc: 80% of patients
with RP who had both SSc-speciﬁc autoantibodies and
capillary abnormalities developed SSc (study-speciﬁc def-
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Table 1. American College of Rheumatology
preliminary classiﬁcation criteria for SSc (adapted, with
permission, from ref. 3)*
1980 preliminary criteria for the classiﬁcation of SSc
Major criterion
Proximal scleroderma: bilateral and symmetric
sclerodermatous changes in any area proximal to the
metacarpophalangeal joints or metatarsophalangeal
joints
Minor criteria
Sclerodactyly: sclerodermatous changes at ﬁngers or
toes only
Digital pitting scars at ﬁngertips or loss of distal ﬁnger
pad substance (pulp loss)
Bilateral basilar pulmonary ﬁbrosis on chest radiograph
To be classiﬁed as SSc, a patient has to fulﬁll the major
criterion OR at least 2 of the 3 minor criteria
* SSc  systemic sclerosis (scleroderma).
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inition) at 15 years (7). Also, there is now a greater under-
standing of the natural history of SSc (including internal
organ involvement) and availability of better diagnostic
tools (11–13).
Based on new knowledge about the pathogenesis of SSc
and better diagnostic modalities to classify patients with
early SSc, the ACR and the European League Against
Rheumatism (EULAR) supported an international working
group to revise the classiﬁcation criteria for SSc. The main
objective of the classiﬁcation criteria was to distinguish
patients with SSc from those without the disease. The
international working group agreed that revised SSc clas-
siﬁcation criteria should meet additional requirements,
and that they 1) should include the complete spectrum of
SSc and should apply to patients that are early as well as
late in the disease process; 2) should include vascular,
immunologic, and ﬁbrotic manifestations; and 3) should
be feasible in daily clinical practice and clinical studies
and be as close as possible to items used for diagnosis in
clinical practice.
Currently, there is uncertainty about which items to
include in classiﬁcation criteria for SSc. To reduce the
number of potential items to a set including the most
promising items, we conducted consensus procedures us-
ing the Delphi technique and the nominal group technique
(NGT) (14) to select a set of items as potentially useful for
the classiﬁcation of SSc.
MATERIALS AND METHODS
Design. This study had 2 phases: item generation and
subsequent item reduction. An internet-based Delphi ap-
proach was used for item generation, whereas internet-
based Delphi rounds and a face-to-face meeting using the
NGT were used for item reduction. These methodologies
have recently been reviewed in detail (14).
International working group and expert panel. The
ACR/EULAR international working group for the classiﬁ-
cation of SSc consisted of 4 members from North America
and 4 members from Europe. The international working
group established a panel of expert diagnosticians in SSc
to advise in the revision of SSc classiﬁcation criteria. The
expert panel consisted of members from both Europe (n 
14) and North America (n  14).
Item generation process: Delphi exercise 1. Potential
items for classiﬁcation criteria were identiﬁed through 2
internet-based consensus exercises, performed separately
and independently by the Scleroderma Clinical Trials
Consortium (SCTC) and the EULAR Scleroderma Trials
and Research (EUSTAR) group (4). For the SCTC exercise,
96 randomly chosen SCTC members were invited to par-
ticipate. During the ﬁrst round of the 3-round SCTC Delphi
exercise, participants were asked to nominate items that
they incorporate in their daily practice to diagnose SSc
(14). The aim of the EUSTAR exercise was slightly differ-
ent and aimed to identify items suitable for diagnosis of
early SSc (4). For the EUSTAR Delphi exercise, 121 items
that were provided by 85 participants were subjected to a
3-round Delphi exercise. The ﬁrst-round item lists of the 2
separate Delphi exercises were collated with removal of
redundancies through consensus by 4 of the committee
members, leading to a list of 168 items.
Item reduction process. For item reduction, the list of
168 items was subjected to 3 rounds of a new internet-
based Delphi exercise using standard methodology and a
face-to-face consensus meeting with members of the expert
panel using the NGT.
Delphi exercise 2. Clinicians with expertise in sclero-
derma from the EUSTAR and SCTC were asked to partic-
ipate by e-mail. One hundred six experts rated the appro-
priateness of the 168 items for classiﬁcation of SSc on a
1–9 scale (where 1  completely inappropriate and 9 
completely appropriate). The appropriateness score of an
item was calculated as the median of the ratings (1–9).
Items with a median appropriateness score of less than 4 in
this round were removed, resulting in a list of 102 items.
NGT. The 102 items were grouped into organ system
domains and autoantibodies. Members of the expert panel
met for a 1-day face-to-face NGT meeting in 2009. The day
before the meeting, the available panelists (n  16) again
individually rated each of the 102 items for appropriate-
ness. Median appropriateness scores were calculated for
all items. To evaluate the level of (dis)agreement regarding
the appropriateness of an item, the percentages of appro-
priateness scores falling in the lowest tertile (1–3) and the
highest tertile (7–9) were calculated. All of the items with
their scores were discussed in detail during the NGT meet-
ing. In the NGT consensus meeting, the 16 experts were
presented the item list and encouraged to discuss each
item, and their opinions were recorded. This process en-
sured that all participants had an opportunity to contrib-
ute. The expert panel suggested by consensus that certain
items be combined and others discarded, resulting in a list
of 23 items.
Delphi exercise 3. Members of the expert panel (n  26
of 28) individually scored each of the 23 items in this next
internet-based Delphi round using the appropriateness
score (1–9), and the median appropriateness score was
calculated. In addition, the experts also chose 10 items
they thought were most appropriate and important to in-
clude from the list of 23, and ranked those 10 items from
most appropriate (rank 1) to least appropriate (rank 10) to
be able to discriminate between items with equal median
appropriateness scores. The 23 items were ranked 1) in
order of the median appropriateness score (1–9) and 2) in
order of the average expert ranking (0–100%). The average
expert ranking was calculated by giving scores to the
ranks: the most favorite item scored 10 points and the least
favorite item scored 1 point. For each item the rank scores
were summed and divided by the theoretical maximum
score (26 raters  10 points  260); they were then ex-
pressed as a percentage (100% maximum). For example, if
10 raters ranked a sign or symptom as 1 (10 points each),
10 rated it as 2 (9 points each), and 6 rated it as 3 (8 points
each), the total score attributed to this sign or symptom is
([10  10]  [10  9]  [6  8])  238. The percentage
Development of Revised Classiﬁcation Criteria for SSc 353
attributed to this sign or symptom is 238/260  92%, and
this percentage was used to determine the ranking of the
particular sign or symptom.
RESULTS
The Delphi exercise and NGT meeting resulted in 23 items
(Table 2). The items from the 1980 SSc classiﬁcation cri-
teria (Table 1) are also included in this list but are not
identical (Table 2). The 23 items include skin thickening,
autoantibodies, nailfold capillary abnormalities, RP, and
organ system involvement deemed feasible and appropri-
ate to be included. The presence of scleroderma (skin
thickening) had the highest average ranking and a median
appropriateness score of 9. The other highly ranked items
included autoantibodies (positivity for anti–topoisomer-
ase I antibodies, anticentromere antibodies, and anti–RNA
polymerase III antibodies), abnormal nailfold capillary
pattern, ﬁngertip ulcers, presence of RP, presence of inter-
stitial lung disease, presence of renal crisis, and presence
of palpable tendon or bursal friction rubs (see Table 3 for
deﬁnitions).
Four items had a median score of 9 (most appropriate)
(Table 2). Loss of ﬁngertip pulp or acroosteolysis, esoph-
ageal dilatation (by imaging), and calcinosis fell below the
highest 10 items but all had a median appropriateness
score of 7. The other 10 items had median appropriateness
scores between 4 and 6.
The median rating generally corresponded with the av-
erage rank. No items with a median appropriateness score
of 4–6 had a “top 10” favorite score above 20%. There was
minimal disagreement for the other items except for gas-
troesophageal reﬂux disease, for which more than 30% of
appropriateness scores fell in the lowest tertile (1–3).
There were no items with a median score below 4.
DISCUSSION
Classiﬁcation criteria for SSc are being updated because
the existing ACR classiﬁcation criteria for SSc may not be
sensitive for early SSc and a signiﬁcant proportion of
patients with lcSSc may not be classiﬁed as SSc with the
previous criteria (2,5,6,10,15,16). The results of these con-
sensus procedures are a ﬁrst step in the process. Using the
Delphi and NGT, we have reduced the number of items to
be considered in developing revised classiﬁcation criteria
for SSc in a prospective cohort study. The 23 items chosen
during the NGT meeting include skin thickening, autoan-
tibodies, nailfold capillary abnormalities, RP, and internal
organ system involvement.
The 4 items in the existing ACR classiﬁcation criteria for
SSc (Table 1), i.e., proximal scleroderma (proximal to the
Table 2. Results of round 3 Delphi exercise (n  26) in order of ranking for appropriateness*
Item
Median
appropriateness
score (1–9)
Appropriateness
scores between
1 and 3, %
Average
sum
rank, %
1 Presence of scleroderma (skin thickening) 9 0 67
2 Positive anti–topoisomerase I antibody 9 0 57
3 Positive anticentromere antibody 9 0 50
4 Positive anti–RNA polymerase III antibody 9 0 34
5 Abnormal nailfold capillary pattern 8 0 50
6 Fingertip ulcers/pitting scars 8 0 33
7 Renal crisis 8 0 28
8 Raynaud’s phenomenon 7 4 27
9 Interstitial lung disease/pulmonary ﬁbrosis 7 0 25
10 Tendon or bursal friction rubs 7 4 22
11 Fingertip pulp loss or acroosteolysis 7 4 7
12 Esophageal dilatation on radiograph or CT 7 16 9
13 Calcinosis, dermal, subcutaneous, or
intramuscular
7 8 4
14 Telangiectasia consistent with SSc 6 4 11
15 Puffy ﬁngers 6 8 10
16 Pulmonary arterial hypertension 6 13 8
17 Positive antinuclear antibody 5 12 9
18 Flexion contractures of the ﬁngers 5 16 2
19 Positive anti–PM-Scl antibodies 5 28 0
20 Reduced FVC percent predicted 5 20 0
21 Reduced DLCO percent predicted 4 24 7
22 Recurrent or persistent gastroesophageal
reﬂux disease
4 44 5
23 Dysphagia for solid foods 4 24 2
* The 23 items were rated according to their appropriateness (where 1  most inappropriate and 9  most appropriate) and raters indicated their 10
most favorite items from 10 (most favorite) to 1 (least favorite). Items were ranked in order of 1) the median appropriateness rating and 2) the top 10
favorites ranking. The median appropriateness score (1–9) was calculated from the scores of the raters. Ratings between 1 and 3 indicate the percentage
of raters that rated the item as inappropriate. Top 10 favorites ranking indicates the average ranking of an item in the top 10, with higher percentages
indicating a higher average rank (100% as maximum). CT  computed tomography; SSc  systemic sclerosis (scleroderma); FVC  forced vital
capacity; DLCO  diffusing capacity for carbon monoxide.
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Table 3. Proposed item deﬁnitions*
Item Deﬁnition
Abnormal nailfold capillary pattern
consistent with SSc
Enlarged capillaries and/or capillary loss with or without pericapillary hemorrhages
Anticentromere antibody or
centromere pattern on
antinuclear antibody test
Positive according to local laboratory standards
Anti–topoisomerase I antibody Positive according to local laboratory standards
Antinuclear antibody Positive according to local laboratory standards
Anti–PM-Scl antibody Positive according to local laboratory standards
Anti–RNA polymerase III antibody Positive according to local laboratory standards
May not be available in all laboratories as part of ENA
Calcinosis Detected either clinically or radiographically
Calcinosis is deﬁned as palpable, dermal and/or subcutaneous, or intramuscular
deposits
Usually located in ﬁngers or toes or over large proximal joints or extensor surfaces of
distal extremities
Reduced DLCO percent predicted According to local laboratory standards, 80% of predicted or lower cut point
Digital pulp loss or acroosteolysis Loss of substance from the ﬁngertip pad as a result of ischemia rather than trauma or
exogenous cause (3)
Acroosteolysis: osteolysis of the distal phalanx/phalanges (27)
Dysphagia for solid foods By history, a substernal discomfort on swallowing or sensation of food being held up or
“stuck” in a retrosternal location
Esophageal dilatation Esophagus dilatated by imaging (barium swallow, chest radiograph, or HRCT of the chest)
Finger ﬂexion contractures Inability to extend ﬁngers to neutral position due to skin or tendon tightening
not due to arthritis deformities, Dupuytren’s contracture, or other conditions
Fingertip ulcers or pitting scars Ulcers or scars not thought to be due to trauma
Digital pitting scars are depressed areas at the tips as a result of ischemia rather than
trauma or exogenous causes
Reduced FVC percent predicted According to local laboratory standards, 80% of predicted or lower cut point
Interstitial lung disease or
pulmonary ﬁbrosis
Pulmonary ﬁbrosis on HRCT or chest radiograph, most pronounced in the basilar
portions of the lungs or presence of “Velcro” crackles on auscultation
Persistent or recurrent
gastroesophageal reﬂux disease
By history, endoscopy, or imaging
Puffy ﬁngers Swollen ﬁngers or toes: a diffuse, usually nonpitting increase in soft tissue mass of the
ﬁngers or toes extending beyond the normal conﬁnes of the joint capsule
Normal ﬁngers or toes are tapered distally with the tissues following the contours of the
digital bone and joint structures
Swelling of the ﬁngers or toes obliterates these contours
Pulmonary arterial hypertension Diagnosed by right heart catheterization
Raynaud’s phenomenon Self-report or reported by a physician with at least a 2-phase color change in ﬁnger(s)
and often toe(s) consisting of pallor, cyanosis, and/or reactive hyperemia in response
to cold exposure or emotion; usually 1 phase is pallor
Renal crisis New onset of a systolic BP 140 mm Hg and a diastolic BP 90 mm Hg, OR a rise in
systolic BP 30 mm Hg compared to usual and rise in diastolic BP 20 mm Hg
compared to usual, AND at least 1 of these features:
1. Serum creatinine: increase of 50% above usual level
2. Proteinuria: 2 by dipstick conﬁrmed by protein: creatine ratio  ULN
3. Hematuria: 2 by dipstick or 10 RBCs/hpf (without menstruation)
4. Thrombocytopenia: 100,000/mm3
5. Hemolysis (fragmented RBC: by blood smear or increased reticulocyte count)
Scleroderma (skin thickening) Skin thickening or hardening anywhere but not due to scarring after injury, trauma, etc.
Telangiectasias In a scleroderma-like pattern are round and well demarcated and found on the hands,
lips, inside of the mouth, and/or large matt-like telangiectasias
Are visible macular dilated superﬁcial blood vessels that collapse upon pressure and ﬁll
slowly when pressure is released; distinguishable from rapidly ﬁlling spider angiomas
with central arteriole and from dilated superﬁcial vessels
Tendon or bursal friction rubs One or more friction rubs detectable at places such as the shoulders, olecranon bursae,
wrists (ﬂexor or extensors), ﬁngers (ﬂexor or extensor), knees, and ankles (Achilles,
peroneal, posterior tibial, or anterior tibial tendons)
* SSc systemic sclerosis (scleroderma); ENA extractable nuclear antigen; DLCO diffusing capacity for carbon monoxide; HRCT high-resolution
computed tomography; FVC forced vital capacity; BP blood pressure; ULN upper limit of normal; RBC red blood cell; hpf high-power ﬁeld.
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metacarpophalangeal joints), sclerodactyly, digital pitting
scars or pulp loss, and bilateral basilar pulmonary ﬁbrosis,
are also included in the list of 23 items and received
relative high rankings. Based on a better understanding of
the role of SSc-speciﬁc autoantibodies and the presence of
nailfold abnormalities as potential diagnostic criteria for
SSc and considering the natural history of SSc, panelists
also rated autoantibodies (antinuclear antibodies, anticen-
tromere, anti–topoisomerase I, anti–RNA polymerase III,
and anti–PM-Scl antibodies) high for appropriateness, af-
ter the presence of skin sclerosis. Other items not in the
1980 criteria that will be tested in the ongoing ACR/EU-
LAR SSc criteria project include early vascular manifesta-
tions (RP, nailfold capillary pattern), skin and subcutane-
ous tissue manifestations (puffy ﬁngers, calcinosis,
telangiectasia), musculoskeletal manifestations (ﬂexion
contractures of the ﬁngers, tendon or bursal friction rubs),
and internal organ involvement (renal crisis, pulmonary
arterial hypertension, interstitial lung disease [reduced
forced vital capacity and reduced diffusing capacity for
carbon monoxide], esophageal dilatation, gastroesopha-
geal reﬂux disease, dysphagia).
Nearly all of the proposed items in the list of 23 can be
considered to be frequently used to diagnose and assess
patients with SSc in clinical practice (12,17–19). For ex-
ample, the presence of skin thickening is a hallmark of the
clinical presentation of SSc and is present in 95% of
patients (12). Other items such as the presence of RP and
SSc-speciﬁc autoantibodies are characteristic of SSc (20).
The absence of sclerodactyly, absence of RP, and/or ab-
sence of antinuclear antibodies and SSc-speciﬁc autoanti-
bodies are used in clinical practice to differentiate SSc
from scleroderma-like disorders such as eosinophilic fas-
ciitis and scleromyxedema (20). Occurring in more than
90% of patients, RP often precedes skin and visceral ﬁbro-
sis by years or decades, particularly in patients with lcSSc
(7,8,21). Nailfold capillary microscopy is a useful nonin-
vasive method of visualizing vascular abnormalities in
SSc. It can be performed easily in the clinic without highly
specialized equipment (22). The presence of dilated cap-
illaries and pericapillary hemorrhage is very common in
SSc, and the presence of these ﬁndings in patients with
isolated RP predicts future evolution to SSc (7,23). How-
ever, it is important to note that nailbed vascular changes
are not unique to SSc because they can occur in other
connective tissue diseases, especially dermatomyositis, in
which RP is less frequent and the autoantibody proﬁle is
different. In late SSc, there may be much dropout of cap-
illaries to the extent that no dilated capillaries can be seen
by usual magniﬁcation.
SSc is also characterized by speciﬁc serum autoantibod-
ies that include anti–topoisomerase I, anticentromere, an-
ti-Th/To, anti–U3 RNP, anti–RNA polymerase I/III, and
others (7,24). These autoantibodies are known predictors
of progression from isolated RP to SSc, internal organ
involvement, and survival in SSc. Antibodies such as anti-
Th/To and anti–U3 RNP, and in some cases RNA polymer-
ase I/III, may have high speciﬁcity for SSc but are not yet
commercially available.
While all 23 signs and symptoms are associated with
SSc, the ﬁnal result of this project is to ﬁnd a combination
of these items that is able to discriminate the presence of
SSc from similar diseases. Some items that generally occur
in patients with SSc, such as RP or positive antinuclear
antibodies, may not discriminate well if they also fre-
quently occur in other systemic connective tissue diseases.
This means that their presence may be useful in prompting
the physician to apply a diagnostic evaluation in which
SSc is just one of the diagnoses to be considered. Other
items are quite speciﬁc for SSc, such as renal crisis or
digital pulp loss, but their occurrence may be too low to be
very useful in discriminating SSc from other diseases.
Then it may be useful to combine certain items, for exam-
ple, “having pulmonary arterial hypertension, interstitial
lung disease, or renal crisis” or “positive for SSc-speciﬁc
autoantibodies.” Moreover, classiﬁcation criteria also
should apply to patients with established disease and ide-
ally also early in the disease process.
The items were tested in existing databases of SSc pa-
tients and patients with similar “SSc mimicking” disor-
ders, such as systemic lupus erythematosus, myositis, or
primary RP (25). Not all items were tested in all databases
and not all “SSc mimicking” disorders were represented,
but the prevalence in SSc and mimickers was compared
and the discriminant validity of many items was very high.
The starting point of the Delphi had been an extensive
list of items derived from the ﬁrst rounds of 2 independent
Delphi exercises by the EUSTAR and by the SCTC. The
EUSTAR Delphi exercise resulted in the identiﬁcation of 3
main domains for SSc diagnosis, i.e., skin, vascular, and
laboratory, whereas RP, puffy ﬁngers, and antinuclear an-
tibodies were considered as “indicators” for referral to a
specialist for potential SSc diagnosis (4). The SCTC Delphi
exercise has been presented as an abstract (26).
We were able to conduct a Delphi exercise using experts
from member institutions of the SCTC and EUSTAR who
have expertise in management of SSc with a good response
rate. Eighty percent of SCTC members answered the ﬁrst
round and the response to the EULAR Delphi was 70%.
Consensus methods such as Delphi and NGT are useful to
apply if choices are to be made in the presence of consid-
erable uncertainty. The proposed 23 items need further
testing using data-driven methods and item reduction.
Most importantly, the discriminatory capacity of the items
should be tested prospectively in patients with SSc and in
patients with diseases that mimic SSc such as eosinophilic
fasciitis, scleromyxedema, systemic lupus erythematosus,
polymyositis/dermatomyositis, primary RP, generalized
morphea, and nephrogenic systemic ﬁbrosis. However,
some of these disorders may be even rarer than SSc. Once
the univariate discriminatory ability of the items is known,
further item reduction and weighting of items for a ﬁnal
criteria set may be required. Lastly, testing in an indepen-
dent data set is needed.
In conclusion, many potential items for revised SSc
criteria have been reduced to 23 items that include clini-
cal, radiographic, and serologic features of SSc that cap-
ture the breadth and depth of the disease. These items are
currently being validated in an international observational
study for their inclusion in revised classiﬁcation criteria
for SSc.
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